Healthcare and Life Sciences Industry Outlook: 2022
My colleagues at FTI have a brand new white paper out surveying well being care leaders on traits to count on in 2022. The information come from a survey of 251 senior resolution makers working in company
communications, investor relations, public affairs, enterprise growth, R&D and advertising and marketing for healthcare and life sciences firms within the U.S. Some key findings:
Drug pricing
Greater than two-thirds (69%) count on vital coverage modifications shall be made on drug pricing below the Biden Administration over the subsequent 12 months.
Fame
Range
Deal-making
Deal-making is anticipated to rise in 2022. Essentially the most vital improve is predicted in healthcare IPO exercise, with 65% (+12% since 2020) anticipating it to be greater in 2022,
and 1 in 4 (24%) anticipating it to be “far greater.” Almost 7 in 10 (65%) count on M&A exercise to be greater in 2022, rising +5% from final yr, and majority (57%) additionally foresee greater SPAC
exercise in 2022 than within the earlier 12 months.
Hybrid vs. in-person office
In terms of planning a return to the office, 78% are optimistic {that a}
workable stability may be discovered. Corporations are, nonetheless, break up of their strategy, with
49% planning to supply a hybrid working strategy, whereas 43% are contemplating returning to pre-pandemic working.
